Artemisinin Combination Therapy Market Expected To Encourage Expansion At CAGR Of 8.5% For The Forecast Period From 2018 To 2025 : Grand View Research Inc.

San Francisco, 6 May 2019: The Report Artemisinin Combination Therapy Market Size, Share & Trends Analysis Report By Type (Artemether+Lumefantrine, Artesunate+Amodiaquine), By Region, And Segment Forecasts, 2018 – 2025

The global Artemisinin Combination Therapy Market size is expected to reach USD 697.9 million by 2025, according to a new report by Grand View Research, Inc., progressing at a CAGR of 8.5% during the forecast period. Rising adoption rate of ACTs coupled with growing government initiatives to combat malaria epidemic is anticipated to stoke the growth of the market. Furthermore, expanding pipeline and new product approvals are driving the market.

Currently, 6 ACTs are recommended by WHO for the treatment of uncomplicated malaria, which are Artemether-Lumefantrine (AL), artesunate-amodiaquine, Artesunate-Mefloquine (AS-AQ), Dihydroartemisinin-Piperaquine (DHA-PPQ), Artesunate-Sulfadoxine-Pyrimethamine (AS-SP), and Pyronaridine-Artesunate (PR-AS). Some of the benefits provided by ACTs are high efficacy and reduced likelihood of developing resistance. Over the years, access to artemisinin combination therapy has expanded considerably. In 2016, ACTs were used as first-line treatment in almost 80 countries.

Increasing R & D initiatives by pharma-emerging countries such as India and China are revving up the adoption rate of ACTs. Rising demand from malaria endemic countries such as Kenya, Uganda, Nigeria, and Congo is poised to augment the market. Pipeline for new antimalarial drugs is widening and some of them have been introduced recently. These are some of the factors that are propelling the ACT market.

WHO states the necessity for treating uncomplicated malaria, the most serious form of the disease, with ACTs as they are the best treatment available. ACTs are recommended over other treatments including Sulfadoxine-pyrimethamine, chloroquine, and artemisinin monotherapies, because parasites have developed resistance to these medicines.

Malaria is one of the most distressing diseases across the globe with more than 200 million new cases reported each year. According to Medicines Malaria Venture (MMV), a total of 445,000 deaths were caused by malaria worldwide in 2016. Malaria epidemic is continuing to increase globally and climate change is projected to fuel the trend.

Access Research Report of Artemisinin Combination Therapy Market @ www.grandviewresearch.com/industry-analysis/artemisinin-combination-therapy-act-market

Further key findings from the report suggest:

• AL was the largest segment in 2017 due to the fact that it was the first ACT to be marketed and prequalified by WHO for its efficacy, safety, and quality. It is available in more than 60 countries and is the only ACT approved by U.S. FDA
• MEA held the largest share in the market for ACTs due to growing initiatives by government and non-government organizations to raise awareness
• Asia Pacific also held a prominent position in the market owing to factors such as large production base of artemisinin herbs coupled with rising access to ACT in this region
• Major players operating in the market are Novartis, Sanofi, Cipla, Ajanta Pharma, Ipca Laboratories, Guilin Pharmaceuticals, and KPC Pharmaceuticals
• Key players are adopting different strategies to increase their market share such as increasing geographic presence, R & D, new product development, and indication extension.

Browse more reports of this category by Grand View Research at: www.grandviewresearch.com/industry/pharmaceuticals

Grand View Research has segmented the global artemisinin combination therapy market on the basis of type and region:

Artemisinin Combination Therapy Type Outlook (Revenue, USD Million, 2014 - 2025)

• Artemether-Lumefantrine
• Artesunate-Amodiaquine
• Dihydroartemisinin-Piperaquine
• Artesunate-Mefloquine
• Artesunate-Sulfadoxine-Pyrimethamine
• Pyronaridine-Artesunate

Artemisinin Combination Therapy Regional Outlook (Revenue, USD Million, 2014 - 2025)

• Asia Pacific
• Latin America
• Middle East & Africa

Access Press Release of Artemisinin Combination Therapy Market @ www.grandviewresearch.com/press-release/global-artemisinin-combination-therapy-act-market

About Grand View Research

Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, we offer market intelligence studies ensuring relevant and fact-based research across a range of industries, from technology to chemicals, materials and healthcare.

For More Information: www.grandviewresearch.com